Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.7% – Here’s Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR) fell 4.7% on Thursday . The company traded as low as $9.36 and last traded at $9.43. Approximately 486,023 shares traded hands during trading, a decline of 84% from the average session volume of 3,063,639 shares. The stock had previously closed at $9.89.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Negative Sentiment: An analyst reportedly downgraded Capricor to “Hold,” citing the FDA’s extension of the review period for deramiocel and changes related to the Duchenne muscular dystrophy program. The delay pushes out a potential regulatory catalyst and may increase uncertainty surrounding the therapy’s approval timeline. Capricor Downgrade to Hold on Deramiocel PDUFA Extension and DMD Change
• Negative Sentiment: Multiple law firms publicized an existing securities class action against Capricor Therapeutics, alleging violations of federal securities laws and misstatements related to clinical data, including the HOPE-3 trial. The alleged class period runs from December 17, 2025, through July 26, 2026, with September 28, 2026, set as the deadline for investors to seek lead-plaintiff status. These announcements do not represent separate confirmed findings, but they highlight potential litigation costs, reputational damage and disclosure risk for CAPR. Rosen Capricor Securities Class Action Deadline
• Neutral Sentiment: The numerous September 3–4 investor notices largely repeat the same class-action deadline and encourage affected shareholders to contact plaintiffs’ firms. They provide little new information about Capricor’s operating performance or deramiocel’s clinical prospects, so the immediate stock impact is likely driven more by the FDA review delay and litigation overhang than by the notices themselves. Kaplan Fox Capricor Investor Notice

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CAPR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Wall Street Zen downgraded Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Piper Sandler raised shares of Capricor Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday. JonesTrading lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Finally, Roth Capital cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a research note on Monday, July 27th. Three equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $29.15.

Capricor Therapeutics Stock Up 1.3%

The company has a market cap of $546.52 million, a P/E ratio of -3.84 and a beta of 0.72. The stock has a 50 day moving average price of $12.52 and a two-hundred day moving average price of $23.80.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.11). Equities analysts anticipate that Capricor Therapeutics, Inc. will post -1.71 EPS for the current year.

Insider Activity

In other news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. The trade was a 68.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 25,000 shares of company stock valued at $759,158 over the last three months. Insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CAPR. Suvretta Capital Management LLC bought a new position in shares of Capricor Therapeutics during the fourth quarter worth approximately $51,533,000. Tang Capital Management LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $49,062,000. RA Capital Management L.P. bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at approximately $43,516,000. California State Teachers Retirement System grew its position in Capricor Therapeutics by 2,261.8% during the second quarter. California State Teachers Retirement System now owns 1,528,478 shares of the biotechnology company’s stock worth $36,806,000 after buying an additional 1,463,762 shares in the last quarter. Finally, Darwin Global Management Ltd. acquired a new stake in Capricor Therapeutics during the fourth quarter worth approximately $23,168,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.